Drug intelligence / Profile preview

KS99

Development stage: Preclinical
Lead developer: The Pennsylvania State University
Modality: Small Molecules

Overview

KS99 is a synthetic isatin analog, specifically 5,7-dibromo-N-(p-thiocyanomethylbenzyl)isatin, developed by researchers at Pennsylvania State University for the treatment of various hematological and solid malignancies. It acts as a multi-target inhibitor, targeting Bruton tyrosine kinase (BTK), AKT, and tubulin polymerization. In preclinical studies, KS99 has demonstrated potent cytotoxic activity against acute myeloid leukemia (AML) cell lines and primary patient samples by inducing apoptosis through the modulation of Mcl-1 and Bcl-2 expression. It has also shown efficacy against multiple myeloma and several solid tumor models.

Other names: 5,7-dibromo-N-(p-thiocyanomethylbenzyl)isatin

Targets

BTK (Bruton tyrosine kinase)STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on KS99.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KS99.

Explore the full profile